Loading
Micrornas / RNA, Untranslated / RNA, Circular · Journal article
Annals of Medicine · June 9, 2026
Raises a question worth testing. It does not answer one.
This narrative review synthesizes evidence that microRNAs, long non-coding RNAs, and circular RNAs regulate aerobic glycolysis in pancreatic ductal adenocarcinoma through multiple pathways including PI3K/AKT/mTOR, Wnt/β-catenin, and HIF-1α. The authors propose ncRNAs as potential diagnostic biomarkers and therapeutic targets, though the review does not provide primary data or systematic evidence synthesis to support practice change.
Journal article. Patients with pancreatic ductal adenocarcinoma.
PDAC has a five-year survival rate below 10%, with advanced disease present in approximately 50% of patients at diagnosis The five-year survival rate for advanced PDAC is approximately 8.5% based on SEER data PDAC incidence is increasing by 0.5–1.0% per year and is projected to become the second-leading cause of cancer mortality by 2030
PDAC incidence is increasing by 0.5–1.0% per year and is projected to become the second-leading cause of cancer mortality by 2030
The review highlights ncRNAs as mechanistic regulators of PDAC glycolysis and proposes them as candidates for biomarker development and metabolic-targeted therapy. However, clinicians should recognize this is a hypothesis-generating synthesis without evidence of validated clinical utility or therapeutic efficacy in patients.
Narrative review summarizing mechanistic roles of non-coding RNAs in PDAC glycolysis without presenting original data or systematic meta-analysis.
As stated by the source record.
Quoted from the source exactly as published.
The review highlights ncRNAs as mechanistic regulators of PDAC glycolysis and proposes them as candidates for biomarker development and metabolic-targeted therapy. However, clinicians should recognize this is a hypothesis-generating synthesis without evidence of validated clinical utility or therapeutic efficacy in patients.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background. Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with a five-year survival rate below 10%, largely due to late diagnosis and rapid metastasis. PDAC cells exhibit profound metabolic reprogramming, particularly enhanced aerobic glycolysis. Non-coding RNAs (ncRNAs), including microRNAs (miRNAs), long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs), have emerged as key regulators of glycolysis in PDAC, although their integrated roles and clinical relevance remain incompletely understood.Main findings. MiRNAs regulate glycolytic flux by targeting key enzymes and signaling pathways, thereby modulating glucose uptake and lactate production. LncRNAs promote glycolysis through pathways such as PI3K/AKT/mTOR, Wnt/β-catenin and p53, or by acting as competing endogenous RNAs. CircRNAs function as miRNA sponges or transcriptional regulators, contributing to metabolic adaptation and chemoresistance. Beyond glycolysis, ncRNAs also influence mitochondrial function, redox balance and tumor microenvironment remodeling. Clinically, several ncRNAs show promise as diagnostic and prognostic biomarkers. Therapeutic strategies targeting ncRNAs, including nano-delivery systems and RNA-based approaches, demonstrate potential for overcoming chemoresistance and enhancing treatment efficacy.Conclusion. NcRNAs play central roles in regulating glycolysis and metabolic adaptation in PDAC and represent promising targets for diagnosis and therapy. Further studies are required to validate key regulatory networks and translate these findings into clinical applications.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.